Murguía-de Sierra MT

Language: Spanish
References: 30
Page: 313-318
PDF size: 94.97 Kb.

Text Extraction

No abstract

REFERENCES

1. Lawn JE, Cousens S, Zupan J, for the Lancet Neonatal Survival Steering Team. Four million neonatal deaths: When? Where? Why? Lancet. 2005; 365: 891-900.

2. Starling EH. The Croonian lectures. I. On the chemical correlation of the functions of the body. Lancet. 1905; 166: 339-41.

3. Silverman WA. Retrolental fibroplasia: A modern parable (Agosto 9, 2005). Disponible en: http://www.neonatology.org

4. Haddad H, Hsia D, Gellis S. Studies on respiratory rate in the newborn: its use in the evaluation of RDS in IDM. Pediatrics. 1956; 17: 204.

5. Liggins GC. Premature delivery of fetal lambs infused with glucocorticoids. J Endocrinol. 1969; 45: 515.

6. Baden M, Bauer CR, Colle E, Klein G, Taeusch HW, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics. 1972; 50: 526.

7. Taeusch HW, Wang NS, Baden M, Bauer CR, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. II. Pathology. Pediatrics. 1973; 52: 850-3.

8. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000; 83: F177-81.

9. O’Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999; 104: 15-20.

10. Yeh TF, Lin YJ, Huang CC, Chen YJ, Tsai WF, Lien YJ. Early postnatal (<12 hrs) dexamethasone therapy for prevention of BPD in preterm infants with RDS-a two year follow-up study. Pediatrics. 1998; 101: e7.

11. Stark AR, Carlo W, Vohr BR, Papile L, Bauer C, Donovan E, et al. National Institute of Child Health and Development Neonatal Research Network: adverse effects of early dexamethasone in extremely-low-birth-weight infants. N Engl J Med. 2001; 344: 95-101.

12. American Academy of Pediatrics Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002; 109: 330-8.

13. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972; 50: 515-25.

14. Crowley P, Chalmers I, Keirse MJNC. The effects of corticosteroid administration before preterm delivery: An overview of the evidence from controlled trials. Br J Obstet Gynaecol. 1990; 97: 11-25.

15. Van Marter LJ, Leviton A, Kuban KCK. Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia. Pediatrics. 1990; 86: 331-6.

16. Morales WJ, Diebel D, Lazar AJ, Zadrozny D. The effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome in preterm gestations with premature rupture of membranes. Am J Obstet Gynecol 1986; 154: 591-5.

17. Gamsu HR, Mullinger BM, Donnai P, Dash CH. Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: Report of a UK multicentre trial. Br J Obstet Gynaecol. 1989; 96: 401-10.

18. Young BK, Klein SA, Katz M. Intravenous dexamethasone for prevention of neonatal respiratory distress: A prospective controlled study. Am J Obstet Gynecol. 1980; 138: 203-9.

19. Doyle LW, Permezel MJ, Kitchen WH. Is there a lower limit for birth-weight/gestational age and antenatal steroid therapy? Aust NZ J Obstet Gynaecol. 1992; 32: 193-5.

20. Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol. 1993; 168: 508-13.

21. White AD, Andrews EB, Weinberg JM. The Exosurf Neonatal TIND Study Group. Factors associated with intraventricular hemorrhage (IVH) in the exosurf neonatal treatment IND (TIND). Pediatr Res. 1992; 31: 263A.

22. Andrews EB, White AD, Weinberg JM. Antenatal steroids and neonatal outcomes in infants receiving surfactants in the Exosurf treatment IND (abstract). Pediatr Res. 1992; 31: 241A.

23. French NP, Hagan R, Evans SF, Godfrey M, Newnham JP. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol. 1999; 180: 114-21.

24. French N, Hagan R, Evans S. Repeated antenatal corticosteroids (CS): behavior outcomes in regional population of very preterm (VP<33W) infants. Pediatr Res. 1998; 43: 214.

25. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA. 1995; 273: 413-8.

26. Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res. 2001; 50: 706-11.

27. Reist M, Marshall KA, Jenner P, Halliwell B. Toxic effects of sulfite in combination with peroxy-nitrite on neuronal cells. J Neurochem. 1998; 71: 2431-8.

28. Halliday HL, Ehrenkrantz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Neonatal Group. Cochrane Database of Systematic Reviews; 2005.

29. Halliday HL, Ehrenkrantz RA, Doyle LW. Moderately early postnatal (7–14 days) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Neonatal Group. Cochrane Database of Systematic Reviews; 2005.

30. Halliday HL, Ehrenkrantz RA, Doyle LW. Delayed (>3 weeks) corticosteroids for chronic lung disease in preterm infants. Cochrane Neonatal Group. Cochrane Database of Systematic Reviews; 2005.